What We're Reading: Page 396
Industry reads hand-picked by our editors
Feb 17, 2015
-
-
Bloomberg
Shire raises 2015 forecast on NPS acquisition
-
-
-
AZ to settle Nexium kickback case for $7.9M
-
Teva's internal probe turns up 'likely' corruption
-
Valeant arranges financing for potential Salix Pharma bid
-
Indian pharma giants scuffle to snap up injectables maker Claris
-
-
Feb 13, 2015
-
-
UPDATED: Sanofi to chop 100 US jobs in oncology R&D, Genzyme reorg
-
Hospira CEO's golden parachute for Pfizer deal: $80 million
-
-
-
GSK broadens vax portfolio with $190M GlycoVaxyn deal
-
Chinese researchers develop nanocarrier for pancreatic cancer drug
-
-
-
Riken stem cell saga continues as Obokata and other scientists face reprimands
Feb 12, 2015
-
Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again
-
Citi analyst: Humira biosims will hurt AbbVie sales more than you think
-
Nanotrending: FDA adopts another nanotech standard
-
Former Merck financial analyst to plead guilty to insider trading
-
-
-
Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too
-
-
US-EU trade agreement not likely until 2017, SOCMA says
-
Former MN gov demands more trial transparency at UMN in wake of '04 suicide
Feb 11, 2015
Feb 10, 2015
-
A faster cure? Achillion med mixed with Sovaldi clears hep C in just 6 weeks
-
-
FDA warning for blockbuster hopeful edoxaban hits Daiichi where it hurts
-
Roche's blockbuster Lucentis nabs fourth FDA approval
-
Pfizer may still be hungry after Hospira deal
-
FDA proposes new consumer-friendly print drug ad guidance
-
-
Arkansas settles Vertex Medicaid suit over pricey Kalydeco
-
-
Passing the torch: Ralph Neas' tenure at the Generic Pharmaceutical Association
Feb 09, 2015
Feb 06, 2015
-
Merck's hep C treatment loses FDA breakthrough status
-
-
-
Promising Roche Parkinson's med causes lung toxicity in monkey trials
-
-
-
U.S. Chamber knocks IP laggards India, Indonesia, Thailand and Vietnam in Asia
-
Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout
-
Study: Drug makers fail to meet adverse-event reporting requirements
-
Trans-Pacific Partnership trade talks fail to resolve patent & IP issues
Previous
